A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

NCT04946890 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia Leukemia

Interventions

DRUG: MRX2843

Sponsor

Betta Pharmaceuticals Co., Ltd.